Laboratorio Reig Jofre : 2018 08 03 - Admission of the trading period of the allotment rights (PDF)
August 03, 2018 at 07:21 am EDT
Share
CNMV Edison, 4 28006 Madrid
Barcelona (Spain), August 3, 2018
RELEVANT FACT
In accordance with the Royal Legislative Decree 4/2015, dated 23 October, which enacts the consolidated text of the Securities Market Act, and in relation to the Relevant Facts dated June 14, 2018 and registration number 266776, and July 17, 2018 and registration number 267937 on the resolutions of the Board of Directors and General Shareholders' Meeting regarding the distribution of dividends through a scrip dividend, LABORATORIO REIG JOFRE SA ("Reig Jofre" or "the Company") hereby informs that:
Friday, August 3, 2018 is the start date of the trading of the eight hundred and ninety-six thousand eight hundred and eighty-nine (896,889) new shares resulting from the conversion of the free-allotment rights of those shareholders who opted for the exchange of rights into new shares within the scrip dividend
As of that date, Reig Jofre's share capital will be set at thirty-two million, five hundred twenty-five thousand and thirty-three euros (32,525,033.50), represented by sixty-five million fifty thousand and sixty-seven (65,050,67) standard shares with a par value of fifty cents (0.50) each, numbered consecutively from 1 to 65,050,067, both inclusive, all of which are fully subscribed and paid up.
Yours faithfully,
Adolf Rousaud
Secretary of the Board of Directors
Attachments
Original document
Permalink
Disclaimer
Laboratorio Reig Jofre SA published this content on 03 August 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 03 August 2018 11:20:04 UTC
Laboratorio Reig Jofre SA, formerly Natraceutical SA, is a Spain-based company primarily engaged in the research, development, manufacturing and marketing of drugs. The Companyâs activities are divided into four business divisions: Industrial Services, providing production services for third parties; Pharma, selling own pharmaceuticals under a range of brands, such as Reig Jofre, Medea, Orravan, Bioglan and Sala; Reaserch and Development (R&D) and Regulatory, including the development of indications for existing molecules, as well as generics and molecular diagnostics, among others; and Biotech, offering biopharmaceutical support services, such as analytical and process development, quality control and assurance, as well as stability studies. The Company also provides nutritional cosmetics, and food supplements, among others. It operates worldwide in Europe, Africa, the Americas, Australia and Asia through a number of subsidiaries, including Chiesi Espana SA and Oryzon Genomics SA.
LABORATORIO REIG JOFRE, S.A. 
